Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
3.820
-0.340 (-8.17%)
At close: Nov 20, 2024, 4:00 PM
2.260
-1.560 (-40.84%)
After-hours: Nov 20, 2024, 7:59 PM EST
Pyxis Oncology Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Pyxis Oncology stock have an average target of 9.57, with a low estimate of 7.00 and a high estimate of 13. The average target predicts an increase of 150.52% from the current stock price of 3.82.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pyxis Oncology stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Initiates $13 | Buy | Initiates | $13 | +240.31% | Nov 8, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $7 | Buy | Reiterates | $7 | +83.25% | Sep 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +83.25% | Aug 16, 2024 |
| Stifel | Stifel | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +161.78% | Aug 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +83.25% | May 16, 2024 |
Financial Forecast
Revenue This Year
13.68M
Revenue Next Year
n/a
from 13.68M
EPS This Year
-1.04
from -1.85
EPS Next Year
-1.21
from -1.04
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 17.0M | n/a | 26.3M | ||
| Avg | 13.7M | n/a | 4.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.92 | -1.03 | -1.02 | ||
| Avg | -1.04 | -1.21 | -1.29 | ||
| Low | -1.26 | -1.32 | -1.83 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.